Reviva Pharmaceuticals (NASDAQ:RVPH) discussed its recent regulatory interactions, financing, and next clinical steps for lead schizophrenia candidate brilaroxazine during a fireside chat featuring company executive “Lax” and analyst Jim. The conversation centered on a planned formulation change ahead of an eventual NDA filing, efforts to extend potential patent protection, and the expected start and timeline for a second Phase 3 registrational study.
Balance sheet and runway
Lax said the company raised $10 million “last month,” bringing total cash to “close to $23 million” on a pro forma basis. He said the financing is intended to support near-term catalysts and provide a longer runway while the company pursues FDA alignment on switching to a new brilaroxazine drug product.
FDA discussions on switching drug product
A major focus was the company’s plan to change the brilaroxazine drug product before filing an NDA. Lax characterized the principal near-term risk as time: he said it can take “about a year” to develop the change, which has contributed to a delay relative to investor expectations for starting the second Phase 3 trial.
He described the long-term benefits as potentially significant, particularly for attracting investors and strategic partners. Lax said Reviva expects FDA feedback “around mid of this year” regarding the proposed switch, and noted that agency feedback for the relevant meeting type could take “around 45 days to a 60 days timeline,” while also acknowledging the timeline is outside the company’s control.
Lax also outlined what the FDA typically expects when a sponsor changes drug product during clinical development: the new product’s safety profile should be “comparable or better,” while efficacy should not materially change. He said Reviva has generated a preclinical package it believes is predictive for clinical translation and expressed confidence the new product will be “equivalent or better” than the prior version, while declining to provide technical details at this stage.
Patent life and partnering considerations
In discussing partnership interest, Lax said feedback from investors and pharmaceutical companies has been that the clinical data “look good” compared with existing therapies on safety and efficacy. However, he said a recurring concern has been the duration of commercial exclusivity.
Lax said Reviva’s composition-of-matter patent expires in “November 2030,” and the company expects a five-year Hatch-Waxman extension for a new chemical entity, which he said would imply exclusivity to about 2035. He suggested that, given the company’s estimated development timeline, exclusivity for schizophrenia alone could be viewed as limited by potential partners and investors, particularly if the company aims to expand into additional indications such as bipolar disorder and major depressive disorder.
To address this, Lax said the company has filed patents tied to the proposed drug product changes and believes the approach could extend patent life to 2046, though he emphasized the patent “is not granted yet.” He said Reviva has been working for roughly a year on the effort, citing the need for regulatory, CMC/formulation, clinical, and IP expertise.
He also referenced industry precedents, including Intra-Cellular Therapies’ CAPLYTA, noting that—based on publicly available information—CAPLYTA’s patent exclusivity changed and that Intra-Cellular was acquired by Johnson & Johnson in January 2025. Jim also pointed to prior CNS acquisitions, including Karuna Therapeutics and Intra-Cellular, as evidence of continued large-pharma interest in the space.
RECOVER-2 Phase 3 timing and design
On clinical plans, Lax said the planned RECOVER-2 Phase 3 study is designed to be “kind of identical” to RECOVER-1, with a global footprint across the U.S., Asia, and Europe. He said most sites from the first study are expected to be re-engaged and that preparatory work to initiate RECOVER-2 has largely been completed.
Jim summarized key parameters as “50 milligrams once daily, 28 days,” with “about 400 patients,” and asked about enrollment speed. Lax said the prior trial delivered top-line data in about 18 months from first patient enrolled during the COVID period, and he expects RECOVER-2 enrollment could be completed in roughly 12 months, with top-line data in about 14 months after starting enrollment, citing electronic data capture and the repeatable trial design. He described an expected start “sometime in the second half of Q3” following FDA feedback, with top-line data anticipated “end of Q4 or early Q1 in 2028.”
Regarding trial footprint, Lax said RECOVER-1 used 22 U.S. sites, 12 in India, and eight in Europe. For RECOVER-2, he said the company is planning around 25 sites in the U.S., with the same eight in Europe and 12 in India, totaling a little over 40 sites, while noting that 5% to 10% of sites may underperform.
Lax also said he sees limited competition for the patient pool at present, citing two companies he believes are planning or running schizophrenia trials, and suggested that could support faster enrollment.
Bioequivalence study as a potential step
Lax said FDA may require a small bioequivalence study as part of the drug product switch. He described it as a routine, single-dose study in healthy volunteers, potentially involving “around 10” subjects, with blood sampling over about a week and overall execution “around four to six weeks.” He added the company is already preparing a protocol and suggested that, even if required, the bioequivalence work may not materially affect the planned timeline.
In closing remarks, Lax reiterated that the “major milestone” ahead is FDA alignment on switching the drug product and said that, with that feedback, Reviva plans to move forward with a potential bioequivalence study and initiation of the next Phase 3 trial. He framed the start of the second registrational trial as establishing the cadence toward top-line data, a potential NDA submission, and eventual approval.
About Reviva Pharmaceuticals (NASDAQ:RVPH)
Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.
The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.
